Insulin Analogues Show Small but Real Benefits for Children with Type 1 Diabetes in Lebanon

Researchers in Lebanon wanted to understand whether insulin analogues—newer, modified forms of insulin—work better than human insulin for children and adolescents with Type 1 diabetes. While previous studies in wealthy countries showed that analogues improved blood sugar control, nobody had studied this question in low- and middle-income countries, where access to modern diabetes care can be limited and humanitarian challenges complicate treatment.

The team gathered data from 45 young people (ages 4 to 18) who wore continuous glucose monitors between 2019 and 2022. These sensors measure blood sugar continuously throughout the day and night, providing a detailed picture of how well insulin is working—much more detailed than traditional blood tests alone.

When young people switched from human insulin to insulin analogues, they spent an additional 26 minutes per day within their target blood sugar range. While that may sound modest, it reflects measurable improvement in daily glycemic control.

The study also found reductions in low blood sugar episodes. Patients experienced 11 fewer minutes of low blood sugar per day overall, and 10 fewer minutes of nighttime lows specifically. Nighttime hypoglycemia is particularly important because it can occur without the person noticing and may interrupt sleep or cause morning complications.

On average, 24-hour mean blood sugar levels were about 6 mg/dl lower with insulin analogues compared to human insulin. The researchers used statistical methods to account for individual differences and to isolate the effect of the insulin type itself.

However, the study also revealed that despite these improvements, blood sugar variability—how much blood sugar swings up and down—remained high for many patients. This suggests that while insulin analogues offer benefits, other factors influencing day-to-day control remain unresolved.

This research is significant because it's the first real-world evidence of insulin analogue effectiveness in a low- to middle-income country facing humanitarian challenges. Lebanon has experienced major crises that affect healthcare access and diabetes management, making it an important setting for understanding whether newer insulin options truly help in difficult conditions.

The improvements found—better time in range and fewer low blood sugar episodes—align with benefits seen in wealthier countries, suggesting that insulin analogues may be a worthwhile priority for young people with Type 1 diabetes, even in resource-limited settings.

The researchers note that further investigation is needed. This study examined one country's experience and used real-world data, which is valuable but also comes with limitations. Larger studies across different regions and healthcare systems could strengthen the evidence.

The findings also highlight that insulin type alone does not solve all blood sugar control challenges. Ongoing support—including access to continuous glucose monitors, education, and psychological support—likely play important roles alongside the insulin choice itself.

Source: Journal of comparative effectiveness research. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.